<SEC-DOCUMENT>0001279569-17-002407.txt : 20171218
<SEC-HEADER>0001279569-17-002407.hdr.sgml : 20171218
<ACCEPTANCE-DATETIME>20171218074815
ACCESSION NUMBER:		0001279569-17-002407
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171215
FILED AS OF DATE:		20171218
DATE AS OF CHANGE:		20171218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		171260333

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of
1934 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of December 2017</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410
</B></P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway,
Vancouver, British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBITS INCLUDED AS PART OF THIS
REPORT </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 87%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 8pt/107% Calibri, Helvetica, Sans-Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit(s)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">News Release Dated December 15, 2017 - ESSA Announces Filing of Prospectus Supplement and an Update to Previously Announced Equity Offering</FONT></P>


</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT><FONT STYLE="font-size: 10pt">
        P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT><FONT STYLE="font-size: 10pt"> I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    December 15, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT><FONT STYLE="font-size: 10pt"> W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED DECEMBER 15, 2017
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><IMG SRC="image_001.jpg" ALT="ESSA Logo (CNW Group|ESSA Pharma Inc)" STYLE="height: 69px; width: 184px"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: bold 24pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">ESSA Announces Filing of Prospectus Supplement
and an Update to Previously Announced Equity Offering</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">HOUSTON, TX&nbsp;and VANCOUVER, Dec. 15, 2017
/CNW/ - ESSA Pharma Inc. (TSXV: EPI; NASDAQ: EPIX) (&quot;<B>ESSA</B>&quot; or the &quot;<B>Company</B>&quot;) announces an update
to its previously announced pricing press release. The Company intends to&nbsp;issue up to 75,000,000 units of the Company (&quot;<B>Units</B>&quot;)
at a price of US$0.20 per Unit (the &quot;<B>Offering Price</B>&quot;) for aggregate gross proceeds of up to US$15 million &nbsp;(the
&quot;<B>Offering</B>&quot;). Each Unit will be comprised of one common share of the Company (a &quot;<B>Common Share</B>&quot;)
and one common share purchase warrant (a &quot;<B>Warrant</B>&quot;).&nbsp; Each Warrant will be exercisable at a price of US$0.22
and entitle the holder thereof to acquire one common share of the Company (a &quot;<B>Warrant Share</B>&quot;) for a period of
18 months following the closing of the Offering, subject to acceleration in certain circumstances.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Offering will be undertaken on a best
efforts basis pursuant to the terms and conditions of an agency agreement dated December 15, 2017 between the Company and the Canadian
agent as the Company's sole agent for the Offering in Canada (the &quot;<B>Canadian Agent</B>&quot;). The price and the number
of Units were determined by negotiation between the Company and the Canadian Agent in the context of the market.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company has granted to the Canadian Agent
an over-allotment option, exercisable at any time up to the 30<SUP>th</SUP> day following the closing date of the Offering, to
arrange for the purchase from the Company of up to that number of additional Units as is equal to 15% of the Units sold under the
Offering on the same basis as the Units to cover the Canadian Agent's over-allocation position, if any, and for market stabilization
purposes.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Units may also be offered for sale in
the United States through United States registered broker dealers appointed by the Canadian Agent. The selling group will be: (a)
paid a cash commission equal to 7.0% of the gross proceeds of the Offering (except in respect of Units issued in certain circumstances
to specified purchasers, in which case the cash commission will be reduced to 3.5%); and (b) issued broker warrants (the &quot;<B>Broker
Warrants</B>&quot;) representing 5% of the aggregate number of Units issued and sold under the Offering. No Broker Warrants will
be issuable with respect to any Units purchased in certain circumstances to specified purchasers. Each Broker Warrant entitles
the holder thereof to acquire one common share of the Company (a &quot;<B>Broker Warrant Share</B>&quot;) at the Offering Price
for a period of 60 months following the date of the Offering.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company intends to use the net proceeds
of the Offering primarily to continue the ongoing preclinical development of the Company's next-generation Aniten compounds. The
net proceeds will also be used for the interest and principal payments on the Company's outstanding debt and for working capital
and general corporate purposes.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company will apply to list the Common
Shares, Warrant Shares and the Broker Warrant Shares on the TSX Venture Exchange (&quot;<B>TSXV</B>&quot;) and the NASDAQ Capital
Market (&quot;<B>NASDAQ</B>&quot;). Listing will be subject to satisfying all of the requirements of the TSXV and the NASDAQ. The
Company expects to close the Offering on or about December 21, 2017, or such other date as may be mutually agreed to by the Company
and the Canadian Agent, subject to satisfaction of customary closing conditions, including, but not limited to, the receipt of
all necessary stock exchange approvals, such as the conditional approval of the TSXV and NASDAQ.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Offering is to be effected in each of
the provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement dated December 15, 2017 to ESSA's base
shelf prospectus dated December 22, 2015 and elsewhere on a private placement basis.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The securities described herein have not been
registered under the United States Securities Act of 1933, as amended (the &quot;<B>U.S. Securities Act</B>&quot;), or any state
securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the United States
or &quot;U.S. persons,&quot; as such term is defined in Regulation S promulgated under the U.S. Securities Act (&quot;<B>U.S. Persons</B>&quot;),
except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements
or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy
any of the Company's securities to, or for the account of benefit of, persons in the United States or U.S. Persons.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><B>Forward-Looking Statement Disclaimer</B><BR>
<I>This release contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the
meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;anticipate&quot;, &quot;believe&quot;, &quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;,
statements that an action or event &quot;may&quot;, &quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot;
be taken or occur, or other similar expressions and includes, but is not limited to, statements about the timing of the closing
of the Offering, the satisfaction and timing of the receipt of required stock exchange approvals and other conditions to closing
of the Offering, the jurisdictions in which the Units will be offered and the intended use of proceeds of the Offering. </I></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><I>Forward-looking statements and information
are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict,
and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied
thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and
are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such
statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties
and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited
to (i) the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; and (iv) general business, market and economic conditions. </I></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><I>Forward-looking information is developed
based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F
dated December 11, 2017 under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile on the SEDAR
website at www.sedar.com, ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR
profile. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements
are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other
circumstances should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned
against attributing undue certainty to forward-looking statements. </I></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><I>Neither the TSXV nor its Regulation Service
Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.</I></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">View original content with multimedia: http://www.newswire.ca/en/releases/archive/December2017/15/c4285.html</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">%CIK: 0001633932</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>For further information: </B>David S. Wood, Chief Financial Officer,
Tel: (778) 331-0962</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">CNW 22:52e 15-DEC-17</P>



<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !# *T# 2(  A$! Q$!_\0
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H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
